-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Harmony Biosciences Hldgs, Raises Price Target to $51

Benzinga·07/31/2026 17:38:59
Listen to the news
Mizuho analyst Graig Suvannavejh maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Outperform and raises the price target from $50 to $51.